|
|
|
| Effects Analysis of Clinical Curative Effect and Immune Function on Inflammatory on Infliximab Combined with Traditional Chinese Medicine Bowel Disease Treatment during Active Stage |
| LIU Wei |
| Panjin Central Hospital, Liaoning Panjin 124010, China |
|
|
|
|
Abstract Objective: To study effects of infliximab (IFX) combined with traditional Chinese medicine (TCM) on clinical curative effect and immune function in inflammatory bowel disease (IBD) treatment during active stage. Methods: 94 IBD patients during active stage were enrolled. According to simple random and voluntary principle, they were divided into control group (8 cases) and study group (56 cases). The control group was treated with IFX, while study group was treated with TCM on basis of control group. The inflammatory cytokines, lymphocyte subsets, scores of TCM syndromes and clinical curative effect before and after treatment was compared between the two groups. Results: The total response rate of treatment in study group was significantly higher than that in control group (χ2=4.351, P<0.05). Before treatment, there were no significant differences in levels of inflammatory factors (CRP, IL-6, TNF-α) between the two groups (P>0.05). After treatment, decrease amplitude of the above indexes in study group was significantly greater than that in control group (P<0.05). Before treatment, there were no significant differences in levels of lymphocyte subsets (NK cells, CD3+, CD4+, CD4+/CD8+) between the two groups (P>0.05). After treatment, increase amplitude of the above indexes in study group was significantly greater than that in control group (P<0.05). Before treatment, scores of TCM syndromes in control group and study group were (14.96±4.50) points and (15.24±4.16) points, respectively (P>0.05). After treatment, scores of TCM syndromes in control group and study group were (7.34±0.68) points and (5.65±0.49) points. Compared with that before treatment, score decrease amplitude in study group was significantly greater than that in the control group (P<0.05). Conclusion: The curative effect of IFX combined with Anchang Yuyang decoction is significant, which can reduce levels of inflammatory factors, enhance levels of lymphocyte subsets, improve total response rate of treatment, improve immune function, reduce scores of TCM syndromes and effectively treat IBD patients during active stage.
|
|
|
|
|
|
[1] 郭雪云,林连捷,王东旭.炎症性肠病口服药物的新进展[J].胃肠病学,2018,23(12):46~49.
[2] 刘敏,吴治华,吴运.安肠愈疡汤加味联合英夫利昔单抗治疗活动期炎症性肠病疗效及对免疫功能的影响[J].现代中西医结合杂志,2018,27(1):52~55.
[3] 郑筱萸.中药新药临床研究指导原则(试行)[M].中国医药科技出版社,2002.
[4] Kaplan G G, Ng S C. Understanding and preventing the gobal increase of inflammatory bowel disease[J]. Gastroenterology, 2017, 152(2):313~321.
[5] 兰聪颖,唐振豪,尚品洁尚品洁教授基于清热温中法运用清温涩肠汤治疗炎症性肠病经验总结[J].陕西中医,2019,40(3):384~386.
[6] 司敏,沈洪,陆玥琳,等.沈洪教授治疗炎症性肠病经验[J].四川中医,2018,23(4):15~17.
[7] 刘志威,王学群,黄碧云.加味安肠愈疡汤联合甲泼尼龙治疗溃疡性结肠炎疗效观察[J].实用中医药杂志,2018,34(12):106~107.
[8] 朱永钦,朱永苹,林寿宁,等.安胃汤防治慢性萎缩性胃炎的方药机制探讨[J].辽宁中医杂志,2017,44(3):644~647.
[9] 刘倩,田洁,张海超,等.调肠愈疡汤口服联合灌肠治疗溃疡性结肠炎63例[J].河南中医,2017,37(5):830~832. |
|
|
|
2020, Vol. 26 
